Pharmacological action

Recombinant luteinizing hormone, identical to the endogenous LH. Participates in the physiological regulation of reproductive function.

Compensates for lack of endogenous LH. Stimulates the production of estradiol, follicles and the formation of graafova bubble.

The introduction lutropina alpha in mid-cycle induces the formation of corpus luteum and ovulation.

Introduction lutropina alpha in postovulyatornom period supports the functioning of the corpus luteum.


After sc administration lutropin alpha rapidly distributed in organs and tissues. The absolute bioavailability is about 60%.

Practically not cumulative.

T 1 / 2 is about 12 hours

Excreted in the urine - less than 5% of the dose.


Treatment of infertility due to hypothalamic-pituitary disorders that cause the contents of LH and FSH in the body.

Dosage regimen

Enter n / k. Initial dose - 75 IU.

Treatment is carried out in combination with preparations of FSH and chHG under the special scheme.

Side effect

Frequently: headache, abdominal pain, pain in the breasts, nausea, vomiting, drowsiness, ovarian cysts.

Possible: reactions at the injection site - pain, redness, itching, swelling, hematoma, ovarian hyperstimulation (pain in the lower abdomen, sometimes combined with nausea, vomiting, weight loss).

In the application of preparations containing LH, in rare cases, possible venous thrombosis, torsion of ovarian cysts and bleeding into the abdominal cavity, ectopic pregnancy (especially with guidance in history to defeat the primary fallopian tubes).


Tumors of the hypothalamic-pituitary area, hyperprolactinemia, adrenal disease and thyroid cancer, persistent increase in the ovaries, ovarian cysts, developmental anomalies of genital organs (which are incompatible with a normal pregnancy), uterine fibroids, metrorrhagia of unknown etiology, estrogenozavisimye tumors (ovarian cancer, uterine cancer, mammary gland), primary ovarian failure, pregnancy, lactation, hypersensitivity to lutropinu alpha.

Application of pregnancy and breastfeeding

Contraindicated during pregnancy and lactation.


Before treatment, check fertility in the patient and her partner.

Lutropin alfa is used in combination with FSH, to standardize the development of follicles containing eggs. Application chHG leads to the release of eggs from the follicle (ovulation).

In the case of ovarian hyperstimulation syndrome should not be used chHG, and the patient should abstain from sex or use barrier contraceptives such as a minimum for 4 days.

Before and during the course of treatment requires careful monitoring of response from the ovaries using ultrasound and blood testing.

There is a higher incidence of multiple pregnancies. To minimize the probability of its occurrence should be observed dosing regimen recommended for the applicable product.